Search bioRxiv⌕ Search

Biology subjects

Roncoli, A.

Publications and source records attributed to Roncoli, A..

2 recordsLinked to original sources

Can Folding Models Tell Binders from Bluffers? Evidence from POISK: The Patent-Derived Antibody Dataset

Structure prediction models are increasingly deployed as zero-shot digital screens in antibody design, operating under the assumption that high folding confidence implies true binding. However, rigorous validation of this premise has been limited by small test sets, narrow target diversity, and the risk of data leakage from training-adjacent structures. Here we introduce POISK: Patent-extracted Organization of Immunoglobulin Sequence Knowledge, a large-scale dataset derived from the US patent literature, comprising 89074 antibody-antigen records extracted from 10110 patents using an LLM-based pipeline. From this resource, we curate a balanced benchmark set of 22494 complexes: 11247 patent-validated binders without a known resolved structure paired with putative non-binders constructed from sequence-similar human repertoire antibodies. Using this dataset, we benchmark six leading structure prediction models (AlphaFold-Multimer, Boltz-2, IntelliFold v2, OpenFold3, Protenix-v1, and Protenix-v2) on their ability to discriminate binders from decoys. The best-performing model, Protenix-v2, achieves 72% pairwise accuracy over all pairs and 87% on the most confident half of predictions, and correctly identifies the true binder from a pool of 50 candidates in 29% of trials; this represents a substantial enrichment over random selection, yet remains far from reliable single-candidate identification. Structural consensus across models also discriminates binders from decoys, with pairwise accuracy reaching 73.1% when three or more models converge on a pose (DockQ>0.23, covering around 54.2% of pairs). Epitope localization remains unreliable: the best model contacts annotated epitope residues in only 62.8% of cases, indicating that binding discrimination does not establish accurate epitope localization. Our results suggest that current folding models provide useful but limited signal for antibody screening and should be complemented by orthogonal methods. We release POISK as a community resource for future benchmarking and model training.

bioinformatics↗

MIMOSA: Guiding De Novo Antibody Design with Natural Interaction Fingerprints

De novo antibody design promises to transform therapeutic antibody and nanobody discovery. Yet, success remains inconsistent across targets, with generative models often yielding no experimentally validated binders. Here we introduce MIMOSA (MIMic-Oriented Structural Antibody generation), a model-agnostic, inference-time framework that constrains diffusion-based antibody design pipelines to reproduce the interaction geometry and chemistry of a target's known cognate binder interface. Rather than searching for a productive interface from scratch, MIMOSA constrains generation around residue identities and geometries already known to support binding, while allowing the generative model to complete the surrounding antibody interface. We test MIMOSA on different interface topologies: contiguous motifs that fit within a single CDR loop and spatially dispersed hotspots distributed across the paratope. Applied without retraining to two architecturally distinct generators (RFAntibody and BoltzGen), this framework delivers experimentally validated binders-achieving sub-micromolar to single-digit nanomolar affinities-at 20-26% hit rates on three targets on which unconstrained methods produce zero or near-zero binders: KEAP1, uPA, and IL-8. By turning any target with a structurally characterised cognate binder into an accessible de novo design problem, this framework broadens the practical reach of generative antibody design to targets where unconstrained approaches currently fail.

bioinformatics↗